Browse medicines, page 5 of 6

Use listed on the medicine record

Gated cardiac blood pool imaging and for the detection of gastrointestinal bleeding sites

Use listed on the medicine record

The first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)‑negative

Use listed on the medicine record

The risk

Use listed on the medicine record

The adjunctive treatment of shock or impending shock due to hemorrhage, burns, surgery or other trauma

Use listed on the medicine record

Rolvedon is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. Limitations of Use Rolvedon is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Use listed on the medicine record

TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen. TROGARZO, a CD4-directed post-attachment HIV-1 inhibitor, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.

Use listed on the medicine record

Neuromyelitis optica spectrum disorder

Use listed on the medicine record

Low-density lipoprotein cholesterol

Use listed on the medicine record

Routine prophylaxis to prevent or reduce the frequency of bleeding episodes

Use listed on the medicine record

ELAHERE ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test [see Dosage and Administration ( 2.1 )].

Use listed on the medicine record

Treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency

Use listed on the medicine record

Asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer

Use listed on the medicine record

TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Use listed on the medicine record

Locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [

Use listed on the medicine record

Iron deficiency anemia

Use listed on the medicine record

Unresectable hepatocellular carcinoma

Use listed on the medicine record

BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BRIUMVI is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 , 14 ).

Use listed on the medicine record

Gallstone formation in obese patients experiencing rapid weight loss

Use listed on the medicine record

Previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved

Use listed on the medicine record

Determinations of total blood and plasma volumes and in protein turnover studies

Use listed on the medicine record

The temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity

Use listed on the medicine record

Relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell

Use listed on the medicine record

Hyperkalemia

Use listed on the medicine record

Blood phenylalanine concentrations

Use listed on the medicine record

Kit for the Preparation of Technetium Tc 99m Pentetate Injection

Use listed on the medicine record

Unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at least one of them

Use listed on the medicine record

The stimulation